Early Access

10-QPeriod: Q2 FY2012

MCKESSON CORP Quarterly Report for Q2 Ended Sep 30, 2011

Filed October 25, 2011For Securities:MCK

Summary

McKesson Corporation's 10-Q filing for the period ending September 30, 2011, showcases solid revenue growth driven primarily by its Distribution Solutions segment, which now includes the recently acquired US Oncology Holdings, Inc. The company reported an increase in revenue for both the quarter and the first six months of the fiscal year, reflecting market growth and strategic acquisitions. While net income saw a slight decrease year-over-year, largely due to a significant increase in litigation charges related to the Average Wholesale Price (AWP) litigation, income from continuing operations demonstrated a positive trend. Despite the impact of AWP litigation charges and an asset impairment charge in the prior year's Technology Solutions segment, the company's financial health appears robust. McKesson maintains a strong balance sheet with increased cash and cash equivalents and a manageable debt-to-capital ratio. The company also continued its commitment to shareholder returns through increased dividends and significant share repurchases. Investors can find reassurance in the company's consistent revenue generation and strategic growth initiatives, though the ongoing legal matters, particularly the AWP litigation, warrant close monitoring.

Financial Statements
Beta
Revenue$30.22B
Cost of Revenue$28.57B
Gross Profit$1.65B
Operating Expenses$1.17B
Operating Income$478.00M
Net Income$296.00M
EPS (Basic)$1.20
EPS (Diluted)$1.18
Shares Outstanding (Basic)246.00M
Shares Outstanding (Diluted)250.00M

Key Highlights

  • 1Total revenues for the quarter ended September 30, 2011, increased by 10% to $30.2 billion, and for the first six months of fiscal year 2012, increased by 9% to $60.2 billion, primarily driven by the Distribution Solutions segment.
  • 2Income from continuing operations for the quarter increased by 16% to $296 million, and for the first six months by 5% to $582 million, indicating operational improvements despite various charges.
  • 3Net income for the quarter decreased by 9% to $296 million, and for the first six months by 7% to $582 million, largely due to a significant rise in Average Wholesale Price (AWP) litigation charges.
  • 4The company completed the acquisition of US Oncology Holdings, Inc. in December 2010 for approximately $2.1 billion, which is expected to expand its specialty pharmaceutical distribution business and add practice management services.
  • 5McKesson renewed its $1.3 billion senior unsecured revolving credit facility in September 2011, extending its maturity to September 2016, with no borrowings outstanding as of the reporting date.
  • 6The company continued its focus on shareholder returns, raising its quarterly dividend and repurchasing approximately $850 million of common stock through accelerated share repurchase programs during the period.
  • 7The AWP litigation reserve increased significantly to $442 million as of September 30, 2011, reflecting ongoing legal proceedings and the settlement of certain claims, which are recorded within the Distribution Solutions segment.

Frequently Asked Questions